Mometasone furoate detailed information

Jump to: navigation, search
Mometasone furoate detailed information
Mometasone furoate.png
Clinical data
Routes of
administration
topical, nasal
ATC code
Pharmacokinetic data
BioavailabilityNasal spray is virtually undetectable in plasma
Protein binding98% to 99%
Metabolismhepatic
Elimination half-life5.8 hours
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC22H28Cl2O4 for Mometasone
C27H30O6Cl2 as Furoate
Molar mass427.361 g/mol

WikiDoc Resources for Mometasone furoate detailed information

Articles

Most recent articles on Mometasone furoate detailed information

Most cited articles on Mometasone furoate detailed information

Review articles on Mometasone furoate detailed information

Articles on Mometasone furoate detailed information in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Mometasone furoate detailed information

Images of Mometasone furoate detailed information

Photos of Mometasone furoate detailed information

Podcasts & MP3s on Mometasone furoate detailed information

Videos on Mometasone furoate detailed information

Evidence Based Medicine

Cochrane Collaboration on Mometasone furoate detailed information

Bandolier on Mometasone furoate detailed information

TRIP on Mometasone furoate detailed information

Clinical Trials

Ongoing Trials on Mometasone furoate detailed information at Clinical Trials.gov

Trial results on Mometasone furoate detailed information

Clinical Trials on Mometasone furoate detailed information at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Mometasone furoate detailed information

NICE Guidance on Mometasone furoate detailed information

NHS PRODIGY Guidance

FDA on Mometasone furoate detailed information

CDC on Mometasone furoate detailed information

Books

Books on Mometasone furoate detailed information

News

Mometasone furoate detailed information in the news

Be alerted to news on Mometasone furoate detailed information

News trends on Mometasone furoate detailed information

Commentary

Blogs on Mometasone furoate detailed information

Definitions

Definitions of Mometasone furoate detailed information

Patient Resources / Community

Patient resources on Mometasone furoate detailed information

Discussion groups on Mometasone furoate detailed information

Patient Handouts on Mometasone furoate detailed information

Directions to Hospitals Treating Mometasone furoate detailed information

Risk calculators and risk factors for Mometasone furoate detailed information

Healthcare Provider Resources

Symptoms of Mometasone furoate detailed information

Causes & Risk Factors for Mometasone furoate detailed information

Diagnostic studies for Mometasone furoate detailed information

Treatment of Mometasone furoate detailed information

Continuing Medical Education (CME)

CME Programs on Mometasone furoate detailed information

International

Mometasone furoate detailed information en Espanol

Mometasone furoate detailed information en Francais

Business

Mometasone furoate detailed information in the Marketplace

Patents on Mometasone furoate detailed information

Experimental / Informatics

List of terms related to Mometasone furoate detailed information

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Overview

Mometasone furoate (also referred to as Mometasone) is a moderately potent glucocorticoid steroid used in the treatment of inflammatory skin disorders (such as eczema and psoriasis), allergic rhinitis (such as hay fever), and asthma for patients unresponsive to less potent corticosteroids. In terms of steroid strength, it is more potent than hydrocortisone, and less potent than dexamethasone.

Schering-Plough markets the medication under the following brand names; Elocon (Elocom) as a cream or ointment for skin conditions, Nasonex as a nasal spray for upper respiratory conditions, Asmanex Twisthaler as a dry powder inhaler (DPI) for lower respiratory conditions.

External links


hu:Mometazon-furoát



Linked-in.jpg